Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Feasibility of a Novel Intervention for At Risk Mental State

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03160092
Recruitment Status : Recruiting
First Posted : May 19, 2017
Last Update Posted : May 19, 2017
Sponsor:
Collaborator:
Norfolk and Suffolk NHS Foundation Trust
Information provided by (Responsible Party):
University of East Anglia

Brief Summary:

Young people with At Risk Mental State (ARMS) may have changes in their thoughts and the way they see or hear things, which they might find odd and distressing. They may be feeling tense, worried and low in mood and may not feel like socialising. They may also experience difficulties with eating and sleeping. For many people these symptoms might not last for very long, but for a small number of people, they might last longer and could become worse (health professionals call this psychosis).

Psychological therapy, which involves talking to a therapist, can help to stop these symptoms from getting worse, stopping psychosis. It can also help to make the symptoms better. Cognitive Behavioural Therapy (CBT) is the treatment that is most recommended to help young people with ARMS. But, this is not always available, can take a long time and is quite expensive. Some research has shown that brief therapy with a therapist who is warm and understanding and helps the young person to make sense of their symptoms, may be as helpful as CBT, and is quicker and cheaper.

This study hopes to develop a treatment like this and to offer it to 12 young people, aged between 16 and 25, who are experiencing the symptoms outlined. Participants will be given four treatment sessions, and will be asked to complete some questionnaires. The study aims to see how they find it and whether it seems to help them. It will also ask professionals who work with these young people what they think about the new therapy. This is a feasibility study so the findings will help us to decide whether more research should be done on this treatment and whether it could be offered in the NHS in the future.


Condition or disease Intervention/treatment Phase
At Risk Mental State Attenuated Psychotic Symptoms Other: Intervention Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Assessing the Feasibility of a Novel Intervention for Young People With At Risk Mental State and Attenuated Positive Psychotic Symptoms: The Viability of Its Use in the NHS and of a Future Trial
Actual Study Start Date : April 11, 2017
Estimated Primary Completion Date : November 1, 2017
Estimated Study Completion Date : September 1, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intervention

Clinical Participants will receive a 4 session individual intervention, which will be delivered by Assistant Practitioners and Assistant Psychologists (who will have received specific training in the delivering of the intervention).

The intervention will target the participant's attenuated positive psychotic symptoms, which will be referred to as: 'unusual' experiences (unless the participant prefers an alternative).

The therapist will focus on creating a therapeutic relationship in which the participant experiences them as warm, accepting and empathic. The aim is for the participant to feel listened to and understood.

The intervention will focus on taking a normalising and non-catastrophising approach to the individual's unusual experiences. The participants will be provided with psychoeducation to support this aim.

Other: Intervention

The intervention aims to:

  • Support the participant to explore their unusual experiences
  • Reduce the distress or anxiety participants feel in response to their unusual experiences, through:

    • Helping them to recognise how common these unusual experience
    • Supporting them to make sense of their unusual experiences
    • Supporting them to understand why they may be experiencing these symptoms
    • Challenging any unhelpful beliefs they hold about their symptoms
  • Help the participant to recognise the triggers to their unusual experiences
  • Support the participant to increase their activities and socialisation

The intervention is not aiming to 'get rid' of the participant's symptoms, but to reduce their distress in response to them, which may result in improved wellbeing and reduced symptoms.





Primary Outcome Measures :
  1. Comprehensive Assessment of At Risk Mental State (CAARMS) - Change in At Risk Symptoms [ Time Frame: 2 months ]
    This is a 30 minute semi-structured interview, measuring the intensity, duration and frequency of subthreshold psychotic symptoms


Secondary Outcome Measures :
  1. Clinical Outcomes in Routine Evaluation Outcome Measure (CORE-OM) - Change in psychological wellbeing [ Time Frame: 2 months ]
    The CORE-OM measures: Psychological wellbeing, functioning, symptoms and risk

  2. Revised Short Version of the Working Alliance Inventory (WAI-SR) [ Time Frame: 2 months ]
    Both clinician and client versions of this measure will be used to assess the therapeutic alliance formed for each participant

  3. Session Rating Scale (SRS) - Completed after each session [ Time Frame: 1 week ]
    Used to measure the participant's views of each session


Other Outcome Measures:
  1. Service User Participant Experience Questionnaire [ Time Frame: 2 months ]
    Measure of the acceptability of the intervention and the study to the participants receiving the intervention (to inform the feasibility aspect of the study)

  2. Interventional Therapist Participant Experience Questionnaire [ Time Frame: 2 months ]
    Measure of the acceptability of the intervention and the study to the clinicians delivering the intervention (to inform the feasibility aspect of the study)

  3. Youth Team Clinicians Participant Experience Questionnaire [ Time Frame: 2 months ]
    Measure of the acceptability of the intervention and the study to clinicians working in NHS Youth Teams (to inform the feasibility aspect of the study)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 25 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

For Service User Participants (Those receiving the intervention)

Inclusion Criteria:

  • 16 - 25 Years Old
  • Meeting criteria for attenuated psychosis on the Comprehensive Assessment of At Risk Mental State (CAARMS; Yung et al., 2005)
  • Has an allocated lead care professional within the Central Norfolk Youth Team
  • Identified by their care-coordinator as having capacity and being appropriate for therapy (including not being deemed at a high risk of being a danger to themselves or others).

Exclusion Criteria:

  • Meeting criteria for psychosis on the CAARMS and/or a previous open referral to an Early Intervention in Psychosis team
  • Change of psychiatric medication within the previous three months
  • Currently receiving psychological therapy
  • Previously had Cognitive Behavioural Therapy for At Risk Mental State

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03160092


Locations
Layout table for location information
United Kingdom
Central Norfolk Youth Team, 80 St Stephens Road Recruiting
Norwich, Norfolk, United Kingdom, NR1 3RE
Contact: Emma Burton, MSc    00000000000    emma.burton@uea.ac.uk   
Sponsors and Collaborators
University of East Anglia
Norfolk and Suffolk NHS Foundation Trust

Layout table for additonal information
Responsible Party: University of East Anglia
ClinicalTrials.gov Identifier: NCT03160092     History of Changes
Other Study ID Numbers: 212935
First Posted: May 19, 2017    Key Record Dates
Last Update Posted: May 19, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Mental Disorders
Psychotic Disorders
Schizophrenia Spectrum and Other Psychotic Disorders